Cordis and Boma Medical Announce Strategic Partnership to Commercialize Groundbreaking Zero-Particle-Loss Peripheral Drug-Coated Balloon Vasecure

Feb 11, 2025 18:53 CST Updated 18:53

BrosMed Medical

High-end Medical Device Designer, Manufacturer, and Distributor

Cordis

Medical Device Manufacturer

February 10Cordis and BrosMed Medical Sign Agreement for Exclusive Distribution of Next-Generation Drug-Coated Peripheral Balloon Dilatation Catheter: Vasecure, the latter adopts a globally pioneering technology, successfully achieving"Zero Loss of Followers" "Real Retention", cracked the peripheral drug-coated balloon"Loss of followers, Repost, Retention"Three Major Challenges Expected to Open a New Era for Peripheral Drug-Coated Balloon Products.

Cordis, one of the global leaders in cardiac and peripheral vascular intervention, will accelerate the commercialization process of its products after signing a nationwide distribution agreement with BrosMed Medical. This collaboration will also help Cordis further expand its peripheral intervention product portfolio, providing a wide range of localized solutions for patients and healthcare providers in China.

World's first innovative technology,

The Era of "Zero Drug Loss" for Peripheral Drug-Coated Balloons Has Begun

In 2009, the world's first drug-coated balloon (DCB) was launched in Europe, marking a new chapter in interventional therapy.

In China, since the launch of the first DCB product, this market has experienced rapid growth. According to Frost & Sullivan, the scale of China's DCB market will reach 6 billion yuan in 2024 and will increase to 14.3 billion yuan in 2030, with a compound annual growth rate of 15.5% from 2024 to 2030.

In addition to the relatively mature field of coronary intervention, in recent years, drug-coated balloon catheters have also made significant progress in the treatment of cerebrovascular diseases and peripheral vascular diseases. Among them, peripheral DCBs have been widely used in the treatment of peripheral artery disease.

Nowadays, peripheral drug-coated balloons have once again achieved innovative breakthroughs.

After years of dedicated research and development, BrosMed Medical has重磅 launched the Archaeopteryx Vasecure drug-coated peripheral balloon dilation catheter,World's first withFull-length Protective SheathThe drug-coated balloon catheter, utilizing patented crystal and coating technology, successfully addresses the three major challenges of peripheral drug-coated balloons: "powder shedding, loading, and retention."Challenges in clinical application provide a brand-new solution for the treatment of peripheral diseases.

The Vasecure Drug-Coated Peripheral Balloon Dilatation Catheter by Arc'teryx adopts a globally pioneering design withFull-length Protective SheathDelivery System, Delivery ProcessZeroPowder shedding, greatly reducing drug loss during the delivery process, minimizing distal vascular embolism caused by drug coating shedding, and enhancing the efficiency of drug transfer to the vascular wall. Additionally, a completely new"MicroCrystal Needle" Drug Crystal DesignAnd patented spray technology，Adopting a brand-new embedded drug delivery model，Improve Reposting Efficiency, while ensuring the drug's effect on the blood vessel wallLong-acting Retention。Excellent product design has led to outstanding clinical outcomes. Clinical trial data for this product show that the late lumen loss (LLL) of the target lesion at 6 months post-operation was only 0.38, and the target lesion revascularization rate (TLR) was just 3.75%.

Full-length Protective Sheath+
Release Handle

“Microcrystalline Needle"Crystal

Currently, the product has been approved for marketing by the NMPA and is suitable for patients with superficial femoral artery (SFA) and popliteal artery (PPA) stenosis or occlusive lesions undergoing percutaneous transluminal angioplasty.

Complementary Advantages, Win-Win Cooperation

Cordis and BrosMed Medical Join Hands to Advance Peripheral Interventional Diagnosis and Treatment

China’s peripheral interventional market is still in the early stage of development, but it features rapid growth and enormous potential. According to QYResearch data, the global market size for peripheral vascular interventional products was approximately USD 9.625 billion in 2023, with China accounting for 9.74%. It is projected that China’s market will grow at a compound annual growth rate (CAGR) of 11% over the next six years, reaching USD 2.06 billion by 2030, outpacing the global growth rate.

In response to numerous unmet clinical needs, the field of peripheral interventional therapy is calling for more innovative products with clinical value. However, if the commercialization path of innovative technologies is to be more stable and smooth, having a competitive edge in product capability alone is not enough.

This time, BrosMed Medical once again chose its "old friend" Cordis to jointly promote the commercial application of the Archaeopteryx Vasecure Drug-Coated Peripheral Balloon Dilatation Catheter.

As one of the global leaders in cardiac and peripheral vascular interventions, Cordis has entered the Chinese market.Nearly ThreeWith a decade of experience and a mature team, after both parties signed the aforementioned national distribution agreement in China, Cordis will leverage its professional and comprehensive marketing network to help BrosMed Medical's Atheros Vasecure drug-coated peripheral balloon dilation catheter quickly penetrate the market.

At the same time, the signing of this agreement will also help Cordis further expand its peripheral intervention product line, fill the gap in drug-coated balloons during the "drug-loading era" of peripheral interventions, and create a new business growth driver.

In recent years, Cordis has strengthened its cooperation with local innovative enterprises to build an innovative ecosystem. At the same time, it has actively promoted the localization of cardiovascular interventions in China, empowered grassroots healthcare, and provided high-quality products and services for patients with cardiovascular diseases.

Previously, Cordis and BrosMed Medical have collaborated on multiple aspects such as R&D, manufacturing, and commercialization in the field of peripheral interventions. In April last year, Cordis China signed a product R&D entrustment agreement and a production entrustment agreement with BrosMed Medical. It is expected that they will jointly launch the SABER .014 Balloon Dilatation Catheter in 2025 to promote the localized development of peripheral interventions in China.

The signing of the latest agreement further deepened the strategic cooperation between Cordis and BrosMed Medical, and also promoted Cordis's goal of providing a wide range of localized product portfolios for Chinese doctors and patients.

Every burst of medical innovation wisdom, to the point where patients' quality of life is truly improved, involves a long journey that cannot be achieved without the joint efforts of industry peers.

Cai Yulun

General Manager of Cordis Greater China Region

“Cordis has always been committed to the development and localized innovation in the field of vascular intervention. This time, by partnering once again with BrosMed Medical, Cordis looks forward to bringing a brand-new experience to vascular interventional therapy. In the future, Cordis will continue to maintain open cooperation, integrating global wisdom with Chinese innovative strength, to launch more innovative products that meet unfulfilled clinical needs, continuously promote changes and development in the field of vascular intervention, and help elevate China's vascular intervention endeavors to new heights.”